Current Trends in Hemoadsorption Therapy in the Field of Heart Failure

Dear Colleagues,

This Special Issue of the Journal of Cardiovascular Development and Disease focuses on current trends in hemoadsorption therapy in the field of heart failure.

It is a great pleasure for our team to act as guest editors for this Special Issue. The incidence of heart failure is projected to increase by almost 50% by 2030 in all Western countries due to an aging population. New concepts, platforms, and devices for mechanical circulatory support (MCS) will continue to be further developed in the near future due to the relative scarcity of transplant organs. Consequently, the use of MCS has grown significantly, particularly as a bridge to transplantation.

Extracorporeal blood purification techniques have recently gained attention in various fields of clinical medicine and especially in heart failure patients, for VAD implantation, during heart transplantation, as well as during ex vivo perfusion in order to improve donor organ function. In the setting of “donation after circulatory death”, ex vivo perfusion combined with hemoadsorption holds particular promise for the preservation of organ function, thus leading to a higher percentage of transplantable organs.

Hemoadsorption has the ability to modulate the immune response not only by attenuating pro-inflammatory cytokines but also by lowering the levels of myoglobin, creatine kinase, lactate, and many other mediators. Moreover, in the clinical setting, it is used postoperatively to decrease the inotropic support.

The aim of this Special Issue is therefore to provide readers with an update of the current use of hemoadsorption technologies in the growing field of heart failure therapy.

Prof. Dr. Daniel Wendt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hemoadsorption in LVAD implantation
• hemoadsorption in ECMO
• hemoadsorption in heart failure
• hemoadsorption in ex-vivo perfusion
• hemoadsorption in transplantation medicine
• extracorporeal techniques/platforms in hemoadsorption therapy
• new scoring algorithms
• hemoadsorption in right heart failure